Aruna Bio
Athens, US · 3 known investors
Find your way into Aruna Bio
150 people in our graph share verified history with the Aruna Bio team — schools, employers, funds. One of them is your warm intro.
Bill Millerunlockedknows Steven Stice · together at University of Illinois Urbana-Champaign (overlapped)
×2knows the team · via University of Illinois Urbana-Champaign
×3knows the team · via University of Georgia
×6knows the team · via Iowa State University
Aruna Bio develops a proprietary neural exosome platform and a lead therapeutic neural cell-derived exosome, AB126, designed to cross the blood-brain barrier. The company targets acute neurological conditions and chronic neurodegenerative diseases through mechanisms that reduce neuro-inflammation and promote neuro-protection and neuro-regeneration.
Founders & leadership
SS
Steven SticeinChief Scientific Officer and DirectorHe has over 25 years of biotechnology research and development experience, including prior co-founding roles at multiple biotech companies and work on pluripotent stem cell-derived therapeutics and cell-based assays; he also serves on scientific advisory boards for the NIH and FDA and co-chairs a leadership position at an Emory-Georgia Tech-UGA regenerative engineering partnership.
HW
Harold W. IngallsChief Financial Officer and Director
TS
Tracey SticeChief Operating Officer and Secretary
Board
JF
John F. Mangan, Jr.Board director
CW
C. William GriffinBoard director
RC
Russell C. LindnerBoard director
BS
Barry StoreyBoard director
DD
Darren DevoreBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$22.4M disclosed across 3 rounds · 2016–2019
▶$13.3MraisedAug 2019 · 81 investors · BiotechnologyRule 506(b)
▶$13.3MraisedAug 2019 · 81 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Darren DeVoreDirector
- C. William GriffinDirector
- Harold IngallsDirector
- Mason IrvingDirector
- John ManganDirector
- Russell LindnerDirector
- Mark SirgoExecutive Officer, Director
- Steven SticeExecutive Officer, Director
- Tracey SticeExecutive Officer
- Barry StoreyDirector
- Al MedwarExecutive Officer
- Offering amount
- $13.3M
- Amount sold
- $13.3M
- First sale
- Jul 2019
- Incorporated
- Corporation, Georgia
- Federal exemptions
- 06b
▶$5.4MraisedJul 2018 · 32 investors · BiotechnologyRule 506(b)
▶$5.4MraisedJul 2018 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Harold IngallsDirector
- Barry StoreyDirector
- C. William GriffinDirector
- John Mangan, Jr.Director
- Mason Irving, IIIDirector
- Darren DeVoreDirector
- Russell LindnerDirector
- Steven SticeExecutive Officer, Director
- Tracey SticeExecutive Officer
- Offering amount
- $6M
- Amount sold
- $5.4M
- First sale
- Jul 2018
- Incorporated
- Corporation, Georgia
- Federal exemptions
- 06b
▶$3.7MraisedApr 2017 · 14 investors · BiotechnologyRule 506(b)
▶$3.7MraisedApr 2017 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John F. Mangan, Jr.Director
- Harold W. IngallsExecutive Officer, Director
- Tracey SticeExecutive Officer
- C. William GriffinDirector
- Russell C. LindnerDirector
- Barry StoreyDirector
- Steven SticeExecutive Officer, Director
- Darren DevoreDirector
- Offering amount
- $3.7M
- Amount sold
- $3.7M
- First sale
- Aug 2016
- Incorporated
- Corporation, Georgia
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 12 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2022 | $346.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $4.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $500K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $225K |
| Environmental Protection Agency (EPA) | Phase II | 2014 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $225K |
| National Science Foundation | Phase I | 2013 | $149.4K |
| Environmental Protection Agency (EPA) | Phase I | 2013 | $80K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $706.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2008 | $189.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2005 | $293.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2005 | $293.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Aruna Bio do?
- Aruna Bio develops a proprietary neural exosome platform and a lead therapeutic neural cell-derived exosome, AB126, designed to cross the blood-brain barrier. The company targets acute neurological conditions and chronic neurodegenerative diseases through mechanisms that reduce neuro-inflammation and promote neuro-protection and neuro-regeneration.
- Who founded Aruna Bio?
- Aruna Bio was founded by Steven Stice.
- Who are Aruna Bio's investors?
- Aruna Bio's investors include Eshelman Ventures, LLC, Evolution VC Partners, GRA Venture.
- How much funding has Aruna Bio raised?
- Aruna Bio has disclosed $22.4M raised across 3 rounds.
- Where is Aruna Bio headquartered?
- Aruna Bio is headquartered in Athens, US.